Skip to content

Advertisement

  • Research note
  • Open Access

Modulation of CaV1.3b L-type calcium channels by M1 muscarinic receptors varies with CaVβ subunit expression

BMC Research Notes201811:681

https://doi.org/10.1186/s13104-018-3783-x

  • Received: 31 July 2018
  • Accepted: 20 September 2018
  • Published:

Abstract

Objectives

We examined whether two G protein-coupled receptors (GPCRs), muscarinic M1 receptors (M1Rs) and dopaminergic D2 receptors (D2Rs), utilize endogenously released fatty acid to inhibit L-type Ca2+ channels, CaV1.3. HEK-293 cells, stably transfected with M1Rs, were used to transiently transfect D2Rs and CaV1.3b with different CaVβ-subunits, allowing for whole-cell current measurement from a pure channel population.

Results

M1R activation with Oxotremorine-M inhibited currents from CaV1.3b coexpressed with α2δ-1 and a β1b, β2a, β3, or β4-subunit. Surprisingly, the magnitude of inhibition was less with β2a than with other CaVβ-subunits. Normalizing currents revealed kinetic changes after modulation with β1b, β3, or β4, but not β2a-containing channels. We then examined if D2Rs modulate CaV1.3b when expressed with different CaVβ-subunits. Stimulation with quinpirole produced little inhibition or kinetic changes for CaV1.3b coexpressed with β2a or β3. However, quinpirole inhibited N-type Ca2+ currents in a concentration-dependent manner, indicating functional expression of D2Rs. N-current inhibition by quinpirole was voltage-dependent and independent of phospholipase A2 (PLA2), whereas a PLA2 antagonist abolished M1R-mediated N-current inhibition. These findings highlight the specific regulation of Ca2+ channels by different GPCRs. Moreover, tissue-specific and/or cellular localization of CaV1.3b with different CaVβ-subunits could fine tune the response of Ca2+ influx following GPCR activation.

Keywords

  • Acetylcholine
  • CaVβ subunit
  • Dopamine
  • L-type calcium current

Introduction

Voltage-gated Ca2+ channels (VGCCs) control membrane excitability, gene expression, and neurotransmitter release [1]. Alterations in these cellular functions occur when GPCR-activated signal transduction cascades modulate VGCCs. In medium spiny neurons (MSNs) of the striatum, GPCRs, including M1Rs and D2Rs, inhibit VGCC activity [2, 3]. These GPCRs specifically inhibit CaV1.3 L-current, decreasing the output of MSNs [3, 4] and may have functional consequences for motor control [5, 6].

Although present in MSNs, M1R signaling has been characterized most thoroughly in superior cervical ganglion (SCG) neurons. M1Rs couple to Gαq and phospholipase C (PLC) to inhibit native L- and N-VGCC currents [79]. This signal transduction cascade, referred to as the slow or diffusible second messenger pathway, is characterized as pertussis toxin (PTX)-insensitive, voltage-independent, and requiring intracellular Ca2+ to function [10]. Our laboratory has identified arachidonic acid (AA) as a critical effector in the slow pathway [9]. Exogenously applied AA inhibits L-current [1113], which in SCG neurons most likely arises from CaV1.3 [14]. Moreover, Ca2+-dependent cytosolic phospholipase A2 (cPLA2) appears critical for release of AA from phospholipids following M1R activation; loss of cPLA2 activity by pharmacological antagonists or gene knockout ablates L-current inhibition [15, 16].

Additionally, D2Rs inhibit L-current via a diffusible second messenger pathway involving phospholipase C (PLC), InsP3, and calcineurin in MSNs [3]. While both GPCRs signal through PLC, they share another commonality: their activation releases AA from striatal neurons [17, 18] and transfected cell lines [19, 20]. Therefore, D2Rs may also inhibit L- (CaV1.3) and N-(CaV2.2) currents via a pathway utilizing cPLA2 to release AA. In the present study, we tested whether the M1R and D2R pathways converge to modulate recombinant L-VGCC activity.

Main text

Materials and methods

Cell culture

Human embryonic kidney cells, stably transfected with the M1 muscarinic receptor (HEK-M1) [a generous gift from Emily Liman, University of Southern California, originally transfected by [21] ] were propagated at 37 °C with 5% CO2 in Dulbecco’s MEM (DMEM)/F12 supplemented with 10% FBS, 1% G418, 0.1% gentamicin, and 1% HT supplement (Gibco Life Technologies). Cells were passaged when 80% confluent.

Transfection

HEK-M1 cells, grown in 12-well plates (~ 60–80% confluent), were transfected with a 1:1:1 molar ratio of CaV1.3b or CaV2.2, α2δ-1 and different CaVβs [22], using Lipofectamine PLUS (Invitrogen) according to the manufacturer’s instructions. Cells were co-transfected with green fluorescent protein (GFP) to identify transfected cells. Constructs for CaV1.3b (+exon11, Δexon32, +exon42a; GenBank accession #AF370009), CaV2.2 (a10, Δexon18a, Δexon24a, +exon31a, +exon37b, +exon46; #AF055477), CaVβ3 (#M88751) and α2δ-1 (#AF286488) were provided by Diane Lipscombe (Brown University). CaVβ1b (#X61394), CaVβ2a (#M80545), and CaVβ4 (#L02315) constructs were provided by Edward Perez-Reyes (University of Virginia). The D4.4R (#AF1199329) construct was provided by Hubert H. M. Van Tol (University of Toronto). D2R cDNA (#NM_000795) was obtained from the UMR cDNA Resource Center (https://www.cdna.org). Per well, a total of 0.5 μg of DNA (of which GFP cDNA was less than 10%) was used following the methods of Roberts-Crowley and Rittenhouse (2009) [13].

Electrophysiology

Whole-cell currents were recorded following the methods of Liu et al. [11]. High resistance seals were established in Mg2+ Tyrode’s (in mM): 5 MgCl2, 145 NaCl, 5.4 KCl, and 10 HEPES, brought to pH 7.50 with NaOH. Once a seal was established and the membrane ruptured, the Tyrode’s solution was exchanged for external bath solution (in mM): 125 NMG-aspartate, 20 Ba-acetate, 10 HEPES, brought to pH 7.50 with CsOH. Only cells with ≥ 0.2 nA of current were used. Data were acquired using Signal 2.14 software (CED) and stored for later analysis on a personal computer. Linear leak and capacitive currents were subtracted from all traces.

Drugs

All chemicals were purchased from Sigma unless otherwise noted. FPL 64176 (FPL), nimodipine (NIM), and oleoyloxyethyl phosphorylcholine (OPC, Calbiochem) were prepared as stock solutions in 100% ethanol. Quinpirole (quin) and Oxotremorine-M (Oxo-M, Tocris) were dissolved in DDW and stored as 10 mM stock solutions at − 70 °C. Stocks were diluted daily to the final concentration by at least 1000-fold with external solution. For ethanol-prepared stocks, the final ethanol concentration was less than 0.1%.

Statistical analysis

Data are presented as the mean ± s.e.m. Data were analyzed for significance using a Student’s paired t-test for two means, or a one-way ANOVA followed by a Tukey multiple-comparison post hoc test. Statistical significance was set at p < 0.05 or < 0.001. Analysis programs included Signal (CED), Excel (Microsoft), and Origin (OriginLab).

Results

Characterization of recombinant CaV1.3 current as L-type in HEK-M1 cells

Whole-cell L-currents, from β3-containing L-channels, elicited from a holding potential of − 60 mV to a test potential of − 10 mV, averaged − 4699 ± 279 pA (n = 3) compared to − 9 ± 1 pA for HEK-M1 cells transfected with only accessory subunits (n = 10, P < 0.001). Lack of current from cells transfected without CaV1.3b, confirmed that HEK-M1 cells exhibit little endogenous Ca2+ current and transfection of accessory subunits does not upregulate endogenous Ca2+ channels. Recombinant current was confirmed as L-type by showing sensitivity to the L-VGCC antagonist NIM. NIM inhibited β3-containing currents (Additional file 1A) in a concentration-dependent manner (Additional file 1B). Currents were also sensitive to FPL, which enhanced current from β2a- and β3-containing channels and produced long-lasting tail currents upon repolarization (Additional file 1C, D). Additionally, FPL produced a slight hyperpolarizing voltage shift in the peak inward current and enhanced current amplitude at all voltages (Additional file 1E). Additional file 1F demonstrates that FPL enhanced the long-lasting tail current in a concentration-dependent manner. These pharmacological and biophysical properties show that transfection of HEK-M1 cells with CaV1.3b and accessory subunits produce currents with L-type characteristics.

The CaVβ-subunit varies the magnitude of CaV1.3 current inhibition by M1Rs

In MSNs, M1R stimulation inhibits L-current in CaV1.2 knockout animals [4]. Only CaV1.2 and CaV1.3 constitute the L-type CaVα1 subunits expressed in brain [23], implying that M1Rs specifically inhibit CaV1.3 current. Using a cell line transfected with only CaV1.3 channels provides molecular proof for the identity of the inhibited channel. Therefore, to determine if activation of M1Rs inhibits CaV1.3 activity, peak current amplitudes were measured prior to and following application of the M1R agonist Oxo-M. Figure 1a compares representative current traces for CaV1.3b coexpressed with β1b, β2a, β3, or β4-subunits in the absence or presence of Oxo-M. After 1 min, Oxo-M significantly inhibited L-current by 58 ± 8% with β1b; 36 ± 12% with β2a; 66 ± 6% with β3; and 72 ± 10% with β4 (Fig. 1c). Oxo-M elicited kinetic changes that were visualized by normalizing individual traces to the end of the 40 ms test pulse (Fig. 1b), which were quantified by measuring TTP and r40 (Fig. 1d). TTP (Fig. 1e) and r40 (Fig. 1f) decreased following Oxo-M with β1b, β3, or β4; however, no changes were detected with β2a (P ≥ 0.11 for TTP; P ≥ 0.40 for r40). These differences in the magnitude of current inhibition and kinetics suggest that the CaVβ-subunit affects M1R modulation of CaV1.3b.
Fig. 1
Fig. 1

CaV1.3b current inhibition and kinetic changes produced by M1R stimulation are CaVβ-subunit dependent. a Representative current traces from CaV1.3b coexpressed with β1b, β2a, β3 or β4 before (black) or 1 min after applying 10 μM Oxo-M (red). b Current traces from a were normalized to the end of the test pulse. c Summary of Oxo-M inhibition of CaV1.3b with different CaVβ-subunits. Maximal inward current amplitudes were measured after the onset of the test pulse using a trough seeking function (peak current). Percent of current inhibition was calculated as: %Iinhib= 100*(ICTLIDRUG)∕ICTL , where ICTL and IDRUG are the average maximum current amplitude of 5 traces prior to and after 1 min of application of test material (unless otherwise noted). d Schematic of quantification of kinetic changes. e, f Summary of kinetic changes (n = 4–6, ***P < 0.001, **P < 0.05) open bars, control; hatched bars, Oxo-M. e Time to peak (TTP) was measured using a minimum seeking function in Signal within the test pulse duration. f Current remaining (r40) was measured from an average of five normalized current traces per condition using the equation: r40 = 100*Iend∕Ipeak , where r40 is the percent of the maximum inward current remaining at the end of a 40 ms test pulse; Iend is the current amplitude at the end of the test pulse; Ipeak is the maximum inward current measured during the test pulse

Dopamine D2 receptors inhibit CaV2.2 but not CaV1.3 currents

Both M1Rs and D2Rs activate pathways involving G proteins, PLC, and AA release (Fig. 2a). However, whether L-current inhibition by D2Rs shows varied inhibition depending on CaVβ-subunit expression has not been examined. Therefore, we coexpressed D2Rs with CaV1.3b, α2δ-1 and different CaVβ-subunits. While Oxo-M inhibited CaV1.3b-β2a currents over time (Fig. 2b), quin, a D2R agonist, had no effect on current amplitude (Fig. 2c) or kinetics (Fig. 2c inset, g). Since CaV1.3b-β2a current shows less inhibition and no kinetic changes with Oxo-M, we tested whether CaV1.3b-β3 current was sensitive to modulation by quin. Figure 2d shows a time course of CaV1.3b-β3 current inhibition by Oxo-M whereas the time course with quin (Fig. 2e) shows no inhibition or kinetic change (Fig. 2e inset, g). Several concentrations of quin were tested but did not inhibit L-current to the same extent as Oxo-M (Fig. 2f). D2Rs appeared to desensitize with 10 μM quin. Application of quin for 1 min to cells co-transfected with the D2R-like family member, D4.4R, inhibited L-current by 8.5 ± 2.5% and did not produce changes in TTP or r40 (Additional file 2).
Fig. 2
Fig. 2

M1Rs but not D2Rs inhibit recombinant L-current. a Comparison of M1R and D2R signaling pathways that inhibit L-VGCC activity. b Time course of Oxo-M applied at time 0 for CaV1.3b-β2a current. c Time course of 10 nM quin applied at time 0 for CaV1.3b-β2a current. Inset: (left) Individual current traces before (black) and after 1 min of quin, scale bar = 0.5 nA. (right) Normalized traces. d Time course of Oxo-M applied at time 0 for CaV1.3b-β3 current. e Time course of 0.5 μM quin applied at time 0 for CaV1.3b-β3 current. Inset: same as c, scale bar = 1 nA. f Concentration–response curve of quin on CaV1.3b-β2a (filled circles) and CaV1.3b-β3 (open circles) currents (n = 2–5). g Summary of kinetic analysis

To confirm that lack of L-current inhibition was not due to poor expression of D2Rs, we repeated the experiment but substituted CaV2.2 for CaV1.3b to serve as a positive control since activated D2Rs also inhibit CaV2.2 [2426]. Quin inhibited CaV2.2 by 45 ± 7% after 30 s and 48 ± 4% after 1 min (Fig. 3a). Inhibition occurred specifically by activating transfected D2Rs because cells transfected without D2Rs showed no response to quin (Fig. 3a, n = 3). Moreover, N-current inhibition by quin occurred in a concentration-dependent manner (Fig. 3b, n = 3–5). Compared to lower concentrations, 10 μM quin resulted in less inhibition; inhibited current did not recover upon wash, suggesting this concentration causes receptor desensitization (data not shown). Thus, our findings indicate that transfected D2Rs functionally express in HEK-M1 cells to modulate CaV2.2, but not CaV1.3b VGCC activity.
Fig. 3
Fig. 3

D2Rs and M1Rs inhibit recombinant N-current demonstrating successful expression of both GPCRs. To demonstrate that D2Rs are functional, HEK-M1 cells were transfected with the D2R, CaV2.2, α2δ1, and a CaVβ subunit plasmids using the same conditions as described in the Methods section and in Additional file 1 legend as described for CaV1.3b. a Time course of CaV2.2-β3 current inhibition by 0.5 μM quin added at time 0 with (filled circles, n = 8, P < 0.001 compared to CTL) or without (open circles, n = 3) co-transfection of D2Rs. b Concentration–response curve of quin on CaV2.2-β3 current (n = 3–5). c Time course of CaV2.2-β3 current inhibition by Oxo-M added at time 0 under CTL conditions (filled circles, n = 5, P < 0.001 compared to CTL) or preincubation for at least 3 min with 10 μM of the PLA2 antagonist, OPC (open circles, n = 5, P < 0.05 compared to Oxo-M alone, ANOVA). d Time course of CaV2.2-β3 current inhibition by 10 (filled triangles) or 50 nM (filled circles) quin under control conditions or preincubated with OPC (open symbols) (n = 1–5). e Representative CaV2.2-β2a currents measured at a test potential of + 20 mV (−PP) from a holding potential of − 90 mV. A 25 ms prepulse to + 120 mV was placed before a second test pulse (+PP) to measure for membrane-delimited inhibition. CTL current (black) or 30 s after application of 0.5 μM quin (grey). f Same as e in the presence of 1 mg/ml BSA. g Time course of CaV2.2-β2a current (−PP, filled circles; +PP, open circles) exposed to 0.5 μM quin at time 0 for 1 min. After washing, current fully recovered; BSA was added for 3 min before addition of BSA/quin. h Summary of CaV2.2-β2a inhibition by quin (n = 9) or BSA/quin (n = 3)

M1R and D2R pathways use different signaling mechanisms to inhibit N-current

To compare D2Rs and M1Rs signaling pathways on CaV2.2 current, we first confirmed that activation of the stably transfected M1Rs could suppress N-current. Indeed, Oxo-M inhibited currents from β3-containing channels by 70 ± 5% after 30 s (Fig. 3c). When incubated with the PLA2 antagonist OPC, cells showed less N-current inhibition by Oxo-M, 14 ± 8% inhibition after 30 s (Fig. 3c). In contrast, low concentrations of quin still suppressed N-current in the presence of OPC (Fig. 3d). Inhibition was relieved by pre-pulse facilitation (Fig. 3e, g, h) and occurred in the presence of BSA, which acts as a scavenger of free AA (Fig. 3f–h), suggesting that quin mediates membrane-delimited inhibition of N-current. These findings suggest that M1Rs and D2Rs do not share a common pathway leading to N-current inhibition.

Discussion

Previously, the CaV1.3b splice variant of L-VGCCs, found in MSNs, had not been specifically tested for modulation by GPCRs. Here, using HEK-M1 cells, we present the novel finding that M1R stimulation inhibits CaV1.3b L-current with the accessory CaVβ-subunit determining the magnitude of inhibition. In contrast, stimulation of transfected D2Rs with quin does not recapitulate L-current inhibition observed in MSNs [3]. Pharmacological sensitivity to both FPL and NIM confirmed that CaV1.3b expressed in HEK-M1 cells behaves similarly to other recombinant CaV1.3 VGCCs [22, 27].

We also report that N-current modulation by the D2R short splice variant appears similar to membrane-delimited inhibition by the D2R long form [24]. In this form of modulation, when G proteins are activated, Gβγ directly binds to and inhibits CaV2.2 which can be reversed by strong prepulses [10, 28]. Indeed, D2R-mediated inhibition of CaV2.2 was independent of PLA2, whereas blockers of PLA2 abolished inhibition by M1Rs. Thus, the membrane-delimited pathway may be at least partially responsible for the inhibition of CaV2.2 by D2Rs in MSNs [25].

In our experiments, the short splice variant of CaV1.3 (CaV1.3b) was unaffected by activation of D2Rs, expressed in HEK-293 cells, similar to a previous report on CaV1.3a, which has a longer C-terminus [24]. Since neither D2R-long inhibited CaV1.3a [24], nor D2R-short inhibited CaV1.3b (Fig. 2f), one possibility is that another channel/receptor combination occurs in vivo; however, D2R-long and short equally couple to Gi proteins [29]. On the other hand, CaV1.3a binds a scaffolding protein found in the postsynaptic density of synapses known as Shank [30]. In MSNs, CaV1.3a requires an association with Shank for current inhibition by D2Rs [4]. Although lack of the longer CaV1.3 C-terminus may explain the absence of channel modulation by D2Rs in our studies, we found that Oxo-M inhibits CaV1.3b currents, showing that this short splice variant of CaV1.3 can be modulated by a GqPCR. Therefore, a missing intermediary protein vital for D2R modulation of CaV1.3b may underlie the lack of inhibition reported here, or D2Rs may not modulate CaV1.3b.

Conclusions

These findings highlight the specific regulation of Ca2+ channels in a CaVβ-subunit dependent manner by different neurotransmitters. While M1R and D2R pathways contain similar signaling molecules and share a common functional output of inhibiting Ca2+ channels, differences between the two cascades exist. Expression and localization of CaV1.3b associated with different CaVβ-subunits in a tissue or cell may dictate how Ca2+ influx is modulated by nearby GPCRs, ultimately affecting Ca2+-dependent processes.

Limitations

Further experiments are needed to determine the differences in signaling between successful CaV1.3b inhibition by M1Rs versus none with D2Rs.

Abbreviations

AA: 

arachidonic acid

cPLA2

Ca2+ dependent, cytosolic phospholipase A2

D2Rs: 

dopaminergic D2 receptors

FPL: 

FPL 64176

GFP: 

green fluorescent protein

GPCRs: 

G protein-coupled receptors

HEK-293 cells: 

human embryonic kidney cells

M1Rs: 

muscarinic M1 receptors

MSN: 

medium spiny neurons

NIM: 

nimodipine

NMG: 

N-methyl-D-glucamine

OPC: 

oleoyloxyethyl phosphorylcholine

Oxo-M: 

Oxotremorine-M

PLA2

phospholipase A2

PLC: 

phospholipase C

PTX: 

pertussis toxin

Quin: 

quinpirole

SCG: 

superior cervical ganglion

TTP: 

time to peak

VGCCs: 

voltage-gated Ca2+ channels

Declarations

Authors’ contributions

MLR conceived of the project, experimental design, collected and analyzed data, and wrote the manuscript. ARR contributed to the experimental design, analysis and editing of the manuscript. Both authors read and approved the final manuscript.

Acknowledgements

We thank José Lemos, Elizabeth Luna, Haley Melikian, Tora Mitra-Ganguli and Edward Perez-Reyes for their feedback.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The accession numbers for the constructs used in this study are as follows: CaV1.3b (+exon11, Δexon32, +exon42a), GenBank accession #AF370009; CaV2.2 (a10, Δexon18a, Δexon24a, +exon31a, +exon37b, +exon46), GenBank accession #AF055477; CaVβ1b, GenBank accession #X61394; CaVβ2a, GenBank accession #M80545; CaVβ3, GenBank accession #M88751; CaVβ4, GenBank accession #L02315; and α2δ-1, GenBank accession #AF286488. All data generated or analyzed during this study are included in this published article (and its additional files).

Consent for publication

Not relevant.

Ethics approval and consent to participate

Not applicable.

Funding

Salary support to Mandy Roberts-Crowley from NIH Kirschstein NRSA (5 TS32 NS07366-09). Research supplies and salary support (ARR) were supplied by AHA (9940225N), NIH (R01-NS34195), and from the University of Massachusetts Medical School.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Physiology, Program in Neuroscience, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA 01655, USA
(2)
Department of Microbiology and Physiological Systems, Program in Neuroscience, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA

References

  1. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005;57(4):411–25.View ArticleGoogle Scholar
  2. Howe AR, Surmeier DJ. Muscarinic receptors modulate N-, P-, and L-type Ca2+ currents in rat striatal neurons through parallel pathways. J Neurosci. 1995;15(1 Pt 1):458–69.View ArticleGoogle Scholar
  3. Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci. 2000;20(24):8987–95.View ArticleGoogle Scholar
  4. Olson PA, Tkatch T, Hernandez-Lopez S, Ulrich S, Ilijic E, Mugnaini E, Zhang H, Bezprozvanny I, Surmeier DJ. G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain. J Neurosci. 2005;25(5):1050–62.View ArticleGoogle Scholar
  5. Stanika RI, Flucher BE, Obermair GJ. Regulation of postsynaptic stability by the L-type calcium channel CaV1.3 and its interaction with PDZ proteins. Curr Mol Pharmacol. 2015;8(1):95–101.View ArticleGoogle Scholar
  6. Berger SM, Bartsch D. The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function. Cell Tissue Res. 2014;357(2):463–76.View ArticleGoogle Scholar
  7. Haley JE, Delmas P, Offermanns S, Abogadie FC, Simon MI, Buckley NJ, Brown DA. Muscarinic inhibition of calcium current and M current in Galpha q-deficient mice. J Neurosci. 2000;20(11):3973–9.View ArticleGoogle Scholar
  8. Shapiro MS, Loose MD, Hamilton SE, Nathanson NM, Gomeza J, Wess J, Hille B. Assignment of muscarinic receptor subtypes mediating G-protein modulation of Ca2+ channels by using knockout mice. Proc Natl Acad Sci USA. 1999;96(19):10899–904.View ArticleGoogle Scholar
  9. Liu L, Rittenhouse AR. Arachidonic acid mediates muscarinic inhibition and enhancement of N-type Ca2+ current in sympathetic neurons. Proc Natl Acad Sci USA. 2003;100(1):295–300.View ArticleGoogle Scholar
  10. Hille B. Modulation of ion-channel function by G-protein-coupled receptors. Trends Neurosci. 1994;17(12):531–6.View ArticleGoogle Scholar
  11. Liu L, Barrett CF, Rittenhouse AR. Arachidonic acid both inhibits and enhances whole cell calcium currents in rat sympathetic neurons. Am J Physiol Cell Physiol. 2001;280(5):C1293–305.View ArticleGoogle Scholar
  12. Liu L, Rittenhouse AR. Effects of arachidonic acid on unitary calcium currents in rat sympathetic neurons. J Physiol. 2000;525(Pt 2):391–404.View ArticleGoogle Scholar
  13. Roberts-Crowley ML, Rittenhouse AR. Arachidonic acid inhibition of L-type calcium (CaV1.3b) channels varies with accessory CaVbeta subunits. J Gen Physiol. 2009;133(4):387–403.View ArticleGoogle Scholar
  14. Lin Z, Harris C, Lipscombe D. The molecular identity of Ca channel alpha 1-subunits expressed in rat sympathetic neurons. J Mol Neurosci. 1996;7(4):257–67.View ArticleGoogle Scholar
  15. Liu L, Roberts ML, Rittenhouse AR. Phospholipid metabolism is required for M1 muscarinic inhibition of N-type calcium current in sympathetic neurons. Eur Biophys J EBJ. 2004;33(3):255–64.PubMedGoogle Scholar
  16. Liu L, Zhao R, Bai Y, Stanish LF, Evans JE, Sanderson MJ, Bonventre JV, Rittenhouse AR. M1 muscarinic receptors inhibit L-type Ca2+ current and M-current by divergent signal transduction cascades. J Neurosci. 2006;26(45):11588–98.View ArticleGoogle Scholar
  17. Tence M, Cordier J, Premont J, Glowinski J. Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture. J Pharmacol Exp Ther. 1994;269(2):646–53.PubMedGoogle Scholar
  18. Bhattacharjee AK, Chang L, Lee HJ, Bazinet RP, Seemann R, Rapoport SI. D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology. 2005;180(4):735–42.View ArticleGoogle Scholar
  19. Felder CC, Kanterman RY, Ma AL, Axelrod J. A transfected m1 muscarinic acetylcholine receptor stimulates adenylate cyclase via phosphatidylinositol hydrolysis. J Biol Chem. 1989;264(34):20356–62.PubMedGoogle Scholar
  20. Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br J Pharmacol. 1998;124(8):1651–8.View ArticleGoogle Scholar
  21. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987;6(13):3923–9.View ArticleGoogle Scholar
  22. Xu W, Lipscombe D. Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci. 2001;21(16):5944–51.View ArticleGoogle Scholar
  23. Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, Gilbert MM, Snutch TP, Catterall WA. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J Cell Biol. 1993;123(4):949–62.View ArticleGoogle Scholar
  24. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC. Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001;85(2):816–27.View ArticleGoogle Scholar
  25. Yan Z, Song WJ, Surmeier J. D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J Neurophysiol. 1997;77(2):1003–15.View ArticleGoogle Scholar
  26. Leroy J, Richards MW, Butcher AJ, Nieto-Rostro M, Pratt WS, Davies A, Dolphin AC. Interaction via a key tryptophan in the I-II linker of N-type calcium channels is required for beta1 but not for palmitoylated beta2, implicating an additional binding site in the regulation of channel voltage-dependent properties. J Neurosci. 2005;25(30):6984–96.View ArticleGoogle Scholar
  27. Safa P, Boulter J, Hales TG. Functional properties of Cav1.3 (alpha1D) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH3 cells. J Biol Chem. 2001;276(42):38727–37.View ArticleGoogle Scholar
  28. Bernheim L, Beech DJ, Hille B. A diffusible second messenger mediates one of the pathways coupling receptors to calcium channels in rat sympathetic neurons. Neuron. 1991;6(6):859–67.View ArticleGoogle Scholar
  29. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. J Biol Chem. 1994;269(37):23120–7.PubMedGoogle Scholar
  30. Zhang H, Maximov A, Fu Y, Xu F, Tang TS, Tkatch T, Surmeier DJ, Bezprozvanny I. Association of CaV1.3 L-type calcium channels with Shank. J Neurosci. 2005;25(5):1037–49.View ArticleGoogle Scholar
  31. Chien AJ, Carr KM, Shirokov RE, Rios E, Hosey MM. Identification of palmitoylation sites within the L-type calcium channel beta2a subunit and effects on channel function. J Biol Chem. 1996;271(43):26465–8.View ArticleGoogle Scholar
  32. Rampe D, Lacerda AE. A new site for the activation of cardiac calcium channels defined by the nondihydropyridine FPL 64176. J Pharmacol Exp Ther. 1991;259(3):982–7.PubMedGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement